TR200000726T2 - Budesonid ve formoterol'ün yeni kullanımı. - Google Patents

Budesonid ve formoterol'ün yeni kullanımı.

Info

Publication number
TR200000726T2
TR200000726T2 TR2000/00726T TR200000726T TR200000726T2 TR 200000726 T2 TR200000726 T2 TR 200000726T2 TR 2000/00726 T TR2000/00726 T TR 2000/00726T TR 200000726 T TR200000726 T TR 200000726T TR 200000726 T2 TR200000726 T2 TR 200000726T2
Authority
TR
Turkey
Prior art keywords
formoterol
budesonide
new use
bulus
treatment
Prior art date
Application number
TR2000/00726T
Other languages
English (en)
Turkish (tr)
Inventor
Bauer Carl-Axel
Trofast Jan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000726(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200000726T2 publication Critical patent/TR200000726T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR2000/00726T 1997-09-19 1998-09-09 Budesonid ve formoterol'ün yeni kullanımı. TR200000726T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use

Publications (1)

Publication Number Publication Date
TR200000726T2 true TR200000726T2 (tr) 2000-09-21

Family

ID=20408325

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00726T TR200000726T2 (tr) 1997-09-19 1998-09-09 Budesonid ve formoterol'ün yeni kullanımı.

Country Status (38)

Country Link
US (2) US7897646B2 (h)
EP (2) EP1210943B1 (h)
JP (1) JP2001517630A (h)
KR (1) KR20010024140A (h)
CN (1) CN1149998C (h)
AR (1) AR013506A1 (h)
AT (2) ATE329599T1 (h)
AU (1) AU757235B2 (h)
BR (1) BR9812325A (h)
CA (1) CA2302700C (h)
CY (1) CY1106156T1 (h)
CZ (1) CZ295250B6 (h)
DE (2) DE69834955T2 (h)
DK (2) DK1014993T3 (h)
EE (1) EE04297B1 (h)
ES (2) ES2182357T3 (h)
HK (1) HK1045812B (h)
HU (1) HUP0003848A2 (h)
ID (1) ID24838A (h)
IL (1) IL134773A (h)
IN (1) IN190791B (h)
IS (1) IS2715B (h)
MX (1) MXPA00002615A (h)
MY (1) MY127812A (h)
NO (1) NO327176B1 (h)
NZ (1) NZ503173A (h)
PL (1) PL190782B1 (h)
PT (2) PT1210943E (h)
RU (1) RU2199322C2 (h)
SA (1) SA98190773B1 (h)
SE (1) SE9703407D0 (h)
SI (2) SI1210943T1 (h)
SK (1) SK285330B6 (h)
TR (1) TR200000726T2 (h)
TW (1) TW546140B (h)
UA (1) UA72446C2 (h)
WO (1) WO1999015182A1 (h)
ZA (1) ZA988516B (h)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
DK1283036T3 (da) * 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
WO2002062317A2 (en) * 2001-02-06 2002-08-15 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP2397034A1 (en) 2005-07-14 2011-12-21 Lithera, Inc. Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment
CA2631492A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
GB2443287B (en) * 2006-10-17 2009-05-27 Lipothera Inc Methods, compositions and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
PT3111927T (pt) 2009-05-29 2020-03-03 Pearl Therapeutics Inc Composições para administração respiratória de agentes ativos e métodos e sistemas associados
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US20110132355A1 (en) * 2009-06-09 2011-06-09 William Gerhart Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
WO2011088413A2 (en) * 2010-01-15 2011-07-21 Lithera, Inc. Lyophilized cake formulations
GB2485885B (en) 2010-11-24 2015-06-17 Neothetics Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
EP2968152B2 (en) 2013-03-15 2022-06-22 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
ES2796177T5 (es) 2015-12-04 2024-10-29 Mexichem Fluor Sa De Cv Composición farmacéutica
CA3103679A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2021076701A1 (en) 2019-10-17 2021-04-22 Trustees Of Boston University Methods and compositions relating to lung function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
CA2024872C (en) 1989-09-08 2002-07-09 James Barry Douglas Palmer Medicaments
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
EP0613371B1 (en) 1991-12-18 2002-03-06 AstraZeneca AB New combination of formoterol and budesonide
PT613371E (pt) 1991-12-18 2002-07-31 Astrazeneca Ab Nova combinacao de formoterol e budesonido
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
JP2000501104A (ja) * 1995-11-24 2000-02-02 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ キノリン誘導体
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
EP1009408A1 (en) 1997-06-27 2000-06-21 Astra Aktiebolag New combination of antiasthma medicaments
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
JP2001517630A (ja) 2001-10-09
HK1045812A1 (en) 2002-12-13
KR20010024140A (ko) 2001-03-26
RU2199322C2 (ru) 2003-02-27
EP1014993A1 (en) 2000-07-05
CA2302700A1 (en) 1999-04-01
CY1106156T1 (el) 2011-06-08
CN1149998C (zh) 2004-05-19
PT1210943E (pt) 2006-09-29
DE69834955T2 (de) 2007-01-25
EE200000145A (et) 2001-02-15
ATE329599T1 (de) 2006-07-15
SK285330B6 (sk) 2006-11-03
US20110097282A1 (en) 2011-04-28
EP1014993B1 (en) 2002-08-14
NO20001401D0 (no) 2000-03-17
US20020042404A1 (en) 2002-04-11
IL134773A (en) 2005-03-20
DE69834955D1 (de) 2006-07-27
EE04297B1 (et) 2004-06-15
CZ295250B6 (cs) 2005-06-15
EP1210943A1 (en) 2002-06-05
DE69807239T2 (de) 2003-04-10
IN190791B (h) 2003-08-23
NZ503173A (en) 2001-08-31
HUP0003848A2 (hu) 2001-08-28
DK1014993T3 (da) 2002-11-11
HK1045812B (en) 2006-12-22
ES2266322T3 (es) 2007-03-01
DK1210943T3 (da) 2006-09-18
ZA988516B (en) 1999-03-19
PT1014993E (pt) 2002-12-31
NO327176B1 (no) 2009-05-04
US20060189587A9 (en) 2006-08-24
MXPA00002615A (es) 2002-04-24
AU757235B2 (en) 2003-02-06
IS2715B (is) 2011-02-15
NO20001401L (no) 2000-03-17
US8461211B2 (en) 2013-06-11
SI1210943T1 (sl) 2006-10-31
ID24838A (id) 2000-08-24
UA72446C2 (uk) 2005-03-15
IS5407A (is) 2000-03-15
CA2302700C (en) 2010-11-23
SI1014993T1 (en) 2003-02-28
TW546140B (en) 2003-08-11
WO1999015182A1 (en) 1999-04-01
CZ2000950A3 (cs) 2000-06-14
AR013506A1 (es) 2000-12-27
BR9812325A (pt) 2000-09-05
PL339295A1 (en) 2000-12-04
SK3892000A3 (en) 2000-12-11
ATE222106T1 (de) 2002-08-15
AU9192898A (en) 1999-04-12
US7897646B2 (en) 2011-03-01
IL134773A0 (en) 2001-04-30
SE9703407D0 (sv) 1997-09-19
DE69807239D1 (de) 2002-09-19
MY127812A (en) 2006-12-29
PL190782B1 (pl) 2006-01-31
CN1271287A (zh) 2000-10-25
ES2182357T3 (es) 2003-03-01
EP1210943B1 (en) 2006-06-14
SA98190773B1 (ar) 2006-10-02

Similar Documents

Publication Publication Date Title
TR200000726T2 (tr) Budesonid ve formoterol'ün yeni kullanımı.
Gorrieri et al. Action refinement
DE69721766D1 (de) Neue arzneiformulierung
FI20115742L (fi) Mometasonifuroaatin käyttö lääkkeen valmistuksessa
ID27606A (id) Penghantaran raloksifen secara pulmonary dan nasal
ID23600A (id) Turunan tiazolidin dan oksazolidin, pembuatan dan penggunaannya untuk pengobatan (pecahan dari p-950453)
IT1307047B1 (it) Apparecchiatura per il trattamento umidificato dell'apnea da sonno.
IS5756A (is) Notkun hreinljósvirks (+) -norkisapríðs við meðhöndlun á öndunarstöðvun, lotugræðgi og öðrum meinum
FR2729298B1 (fr) Structure absorbante ayant une permeabilite aux liquides amelioree, et produits absorbants l'incorporant
CA2195093A1 (en) Use of droloxifene for the treatment of prostatic diseases, endometriosis and obesity
TR28384A (tr) Flüoroalifatik -ve karboksil- iceren terminal gruplarina sahip polisilokzanlar, bunlarin hazirlanmasi, ve lifli malzemelerin muamelesinde kullanimlari.
ID30116A (id) Turunan-turunan piridopiranoazepin, pembuatannya dan penggunaan terapinya
AU2002308348A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
MXPA03008739A (es) Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores.
ES2167401T3 (es) Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias.
DE69324826D1 (de) Gegen Papillomaviren wirksame 2',5'-OLIGOADENYLAT-2',3'-CYCLOPHOSPHATE und 2',5'-OLIGOADENYLATE
FI970100L (fi) Muunnetun superantigeenin ja kohdetta etsivän yhdisteen välinen konjugaatti ja konjugaatin käyttö
FI956298L (fi) 3-fenyyli-isokinolin-1(2H)-oneja, niiden valmistus ja terapeuttinen käyttö
NO991619L (no) Anvendelse av en H+, K+-ATPase-inhibitor i behandlingen av nesepolypper
PL345325A1 (en) Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
MD980129A (en) Antiherpetic remedy
FI965172L (fi) Uusia amido-kinoksaliinidioneja, niiden valmistus ja käyttö
FR2728596B1 (fr) Degrilleur, notamment du type courbe
MANZAI The Home-cared Role of Physiatrists Who Work in Rehabilitation Center and Other Official Hospital
Yoon et al. The Institutionalization of Science and Technology Practice and Policy formulation